Form 4: Vertex Pharmaceuticals EVP and CMO Carmen Bozic Reports Stock Sale
SEC Form 4
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 2,280 shares of common stock at a price of $445.56 on May 29, 2024, according to a recent SEC filing.
Summary
- On May 29, 2024, Carmen Bozic, the Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals, sold 2,280 shares of Vertex Pharmaceuticals' common stock.
- The sale was executed at a price of $445.56 per share.
- Following the transaction, Bozic directly owns 34,659 shares of Vertex Pharmaceuticals' common stock.
- The transaction was made pursuant to a company-approved trading plan under Rule 10b5-1, which was entered into on February 27, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine stock sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.
Industry Context
Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. Rule 10b5-1 plans are designed to allow insiders to trade without being accused of trading on non-public information.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of entry into Rule 10b5-1 trading plan |
| 05/29/2024 | Date of stock sale transaction |
| 05/31/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.